Accueil / Le Coin du GSF

Le Coin du GSF

Bann_Sarcomes_coin_du_GSF_02

Agenda

Les 17èmes Annuelles du GSF-GETO  se dérouleront en juin 2022 à Toulouse.

Réunion des oncologues médicaux du GSF-GETO – 10/12/2021 – Institut Curie

 

 

Recommandations

  • Dans le Bulletin du Cancer, nous vous invitons à consulter la publication des recommandations du groupe pour la prise en charge des patients en période d’épidémie COVID https://linkinghub.elsevier.com/retrieve/pii/S0007455120301600 . Lire aussi l’article Recommandations du Groupe Sarcome Français en période COVID-19

 

Vie du groupe

Focus sur INTERSARC

Labellisé par l’INCa depuis Octobre 2014, INTERSARC est un réseau de groupes coopérateurs français à dimension internationale dans le domaine des sarcomes. Les groupes coopérateurs représentés sont les suivants : GSF/GETO, SOFCOT,SFCO, UNICANCER, GO AJA, INFO Sarcomes, SOS Desmoïde.

Les objectifs d’INTERSARC sont

  • Favoriser la coopération entre les différentes sociétés scientifiques et les associations de patients afin d’améliorer la qualité de la prise en charge initiale des patients atteints de sarcomes
  • Favoriser la participation aux essais cliniques dans les domaines des sarcomes et des tumeurs conjonctives rares
  • Susciter une réflexion en amont entre ces différents partenaires afin d’identifier les questions pertinentes pour la prise en charge de ces pathologies et de mettre en place un programme stratégique de recherche pour y répondre.

Courant mars 2020, InterSarc après échanges/discussions a apporté son soutien aux projets suivants, qui viennent d’être déposé à l’appel d’offre du PHRC

 INTERSARC

Veille Bibliographique

Pour visualiser la veille bibliographique Sarcomes, cliquez-ici

Pour consulter les Newsletters au format PDF, Édition du 22/07/2021

 

Publications récentes

Nos dernières publications sont les suivantes :

 

  1. Bonvalot S, Wunder J, Gronchi A, Broto JM, Turcotte R, Rastrelli M, Papai Z, Radaelli S, Lindner LH, Shumelinsky F, Cubillo A, Rutkowski P, Demaire C, Strens D, Nalbantov G. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. Eur J Surg Oncol. 2021 Aug;47(8):2166-2172. doi: 10.1016/j.ejso.2021.02.024. Epub 2021 Feb 26. PMID: 33676792.
  2. Fayet Y, Tétreau R, Honoré C, Le Nail LR, Dalban C, Gouin F, Causeret S, Piperno-Neumann S, Mathoulin-Pelissier S, Karanian M, Italiano A, Chaigneau L, Gantzer J, Bertucci F, Ropars M, Saada-Bouzid E, Cordoba A, Ruzic JC, Varatharajah S, Ducimetière F, Chabaud S, Dubray-Longeras P, Fiorenza F, De Percin S, Lebbé C, Soibinet P, Michelin P, Rios M, Farsi F, Penel N, Bompas E, Duffaud F, Chevreau C, Le Cesne A, Blay JY, Le Loarer F, Ray-Coquard I. Determinants of the access to remote specialised services provided by national sarcoma reference centres. BMC Cancer. 2021 May 29;21(1):631.PMID: 34049529
  3. Le Cesne A, Blay JY, Cupissol D, Italiano A, Delcambre C, Penel N, Isambert N, Chevreau C, Bompas E, Bertucci F, Chaigneau L, Piperno-Neumann S, Salas S, Rios M, Guillemet C, Bay JO, Ray-Coquard I, Haddag L, Bonastre J, Kapso R, Fraslin A, Bouvet N, Mir O, Foulon S. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol. 2021 Aug;32(8):1034-1044.PMID: 33932507

Mais aussi :

  1. de Pinieux G, Karanian M, Le Loarer F, Le Guellec S, Chabaud S, Terrier P, Bouvier C, Batistella M, Neuville A, Robin YM, Emile JF, Moreau A, Larousserie, F, Leroux A, Stock N, Lae M, Collin F, Weinbreck N, Aubert S, Mishellany F, Charon-Barra C, Croce S, Doucet L, Quintin-Rouet I, Chateau MC, Bazille C, Valo, I, Chetaille B, Ortonne N, Brouchet A, Rochaix P, Demuret A, Ghnassia JP, Mescam, L, Macagno N, Birtwisle-Peyrottes I, Delfour C, Angot E, Pommepuy I, Ranchere D,Chemin-Airiau C, Jean-Denis M, Fayet Y, Courrèges JB, Mesli N, Berchoud J,Toulmonde M, Italiano A, Le Cesne A, Penel N, Ducimetiere F, Gouin F, Coindre,JM, Blay JY; NetSarc/RePPS/ResSos and French Sarcoma Group- Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One. 2021 Feb 25;16(2):e0246958. doi:10.1371/journal.pone.0246958. PMID: 33630918
  2. Bompas E, Martin V, Meniai F, Toulmonde M, Marec-Berard P, Claude L, Ducimetiere F, Chargari C, Minard-Colin V, Corradini N, Laurence V, Piperno-Neumann S, Defachelles AS, Bernier V, Italiano A, Orbach D, Blay JY, Gaspar N, Berlanga P. Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. Bull Cancer. 2021 Feb;108(2):163-176. doi: 10.1016/j.bulcan.2020.10.009. Epub 2021 Jan 14. PMID:33455736.
  3. Toulmonde M, Lucchesi C, Verbeke S, Crombe A, Adam J, Geneste D, Chaire V, Laroche-Clary A, Perret R, Bertucci F, Bertolo F, Bianchini L, Dadone-Montaudie B, Hembrough T, Sweet S, Kim YJ, Cecchi F, Le Loarer F, Italiano A. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. EBioMedicine. 2020 Dec;62:103131. doi:10.1016/j.ebiom.2020.103131. Epub 2020 Nov 28. PMID: 33254023; PMCID: PMC7708794.

et aussi :

  1. de Pinieux G, Karanian M, Le Loarer F, Le Guellec S, Chabaud S, Terrier P, Bouvier C, Batistella M, Neuville A, Robin YM, Emile JF, Moreau A, Larousserie, F, Leroux A, Stock N, Lae M, Collin F, Weinbreck N, Aubert S, Mishellany F, Charon-Barra C, Croce S, Doucet L, Quintin-Rouet I, Chateau MC, Bazille C, Valo, I, Chetaille B, Ortonne N, Brouchet A, Rochaix P, Demuret A, Ghnassia JP, Mescam, L, Macagno N, Birtwisle-Peyrottes I, Delfour C, Angot E, Pommepuy I, Ranchere D,Chemin-Airiau C, Jean-Denis M, Fayet Y, Courrèges JB, Mesli N, Berchoud J,Toulmonde M, Italiano A, Le Cesne A, Penel N, Ducimetiere F, Gouin F, Coindre,JM, Blay JY; NetSarc/RePPS/ResSos and French Sarcoma Group- Groupe d’Etude des Tumeurs Osseuses (GSF-GETO) networks. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One. 2021 Feb 25;16(2):e0246958. doi:10.1371/journal.pone.0246958. PMID: 33630918
  2. Bompas E, Martin V, Meniai F, Toulmonde M, Marec-Berard P, Claude L, Ducimetiere F, Chargari C, Minard-Colin V, Corradini N, Laurence V, Piperno-Neumann S, Defachelles AS, Bernier V, Italiano A, Orbach D, Blay JY, Gaspar N, Berlanga P. Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. Bull Cancer. 2021 Feb;108(2):163-176. doi: 10.1016/j.bulcan.2020.10.009. Epub 2021 Jan 14. PMID:33455736.
  3. Toulmonde M, Lucchesi C, Verbeke S, Crombe A, Adam J, Geneste D, Chaire V, Laroche-Clary A, Perret R, Bertucci F, Bertolo F, Bianchini L, Dadone-Montaudie B, Hembrough T, Sweet S, Kim YJ, Cecchi F, Le Loarer F, Italiano A. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. EBioMedicine. 2020 Dec;62:103131. doi:10.1016/j.ebiom.2020.103131. Epub 2020 Nov 28. PMID: 33254023; PMCID: PMC7708794.
  4. Crombé A, Kind M, Ray-Coquard I, Isambert N, Chevreau C, André T, Lebbe C, Cesne AL, Bompas E, Piperno-Neumann S, Saada E, Bouhamama A, Blay JY, Italiano A; French Sarcoma Group. Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During SystemicTherapy-A Multicenter Study by the French Sarcoma Group. AJR Am J Roentgenol.2020 Sep 29:1-10. doi: 10.2214/AJR.19.22635. Epub ahead of print. PMID:32991215.
  5. FGM 2025 Workflow Study Group (Alliance nationale des Sciences de la Vie et de la Santé), Auzanneau C, Bacq D, Bellera C, Blons H, Boland A, Boucheix M,Bourdon A, Chollet E, Chomienne C, Deleuze JF, Delmas C, Dinart D, Espérou H,Geillon F, Geneste D, Italiano A, Jean D, Khalifa E, Laizet Y, Laurent-Puig P,Lethimonnier F, Lévy-Marchal C, Lucchesi C, Malle C, Mancini P, Mathoulin-Pélissier S, Meyer V, Marie-Ange P, Perkins G, Sellan-Albert S, Soubeyran I,Wallet C. Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025,plan. ESMO Open. 2020 Jul;5(4):e000744. doi: 10.1136/esmoopen-2020-000744. PMID:32713836; PMCID: PMC7383956.
  6. 3: Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18. PMID: 32421444.
  7. Amadeo B, Penel N, Coindre JM, Ray-Coquard I, Ligier K, Delafosse P, Bouvier AM, Plouvier S, Gallet J, Lacourt A, Coureau G, Monnereau A, Mathoulin-Pélissier S, Desandes E. Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM). BMC Cancer. 2020 Mar 6;20(1):190. doi: 10.1186/s12885-020-6683-0. PMID: 32138705; PMCID: PMC7059296.
  8. Pannier D, Cordoba A, Ryckewaert T, Robin YM, Penel N. Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis. Crit Rev Oncol Hematol. 2019 Nov;143:62-66. doi: 10.1016/j.critrevonc.2019.08.007. Epub 2019 Aug 31. PubMed PMID: 31494310
  9. Piperno-Neumann S, Ray-Coquard I, Occean BV, Laurence V, Cupissol D, Perrin C, Penel N, Bompas E, Rios M, Le Cesne A, Italiano A, Anract P, de Pinieux G, Collard O, Bertucci F, Duffaud F, Le Deley MC, Delaye J, Brugieres L, Blay JY.. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study..Int J Cancer. 2020 Jan 15;146(2):413-423. doi: 10.1002/ijc.32526. Epub 2019 Jul 19..PubMed PMID: 31246277
  10. Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A.Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.Lancet Oncol. 2019 Sep;20(9):1263-1272. doi: 10.1016/S1470-2045(19)30276-1. Epub 2019 Jul 19.PubMed PMID: 31246277
  11. Gougis P, Palmieri LJ, Funck-Brentano C, Paci A, Flippot R, Mir O, Coriat R.Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use.
    Crit Rev Oncol Hematol. 2019 Sep;141:112-124. doi: 10.1016/j.critrevonc.2019.06.006. Epub 2019 Jun 16. PubMed PMID: 31276964
  12. Blay JY, Honoré C, Stoeckle E, Meeus P, Jafari M, Gouin F, Anract P, Ferron G, Rochwerger A, Ropars M, Carrere S, Marchal F, Sirveaux F, Di Marco A, Le Nail LR, Guiramand J, Vaz G, Machiavello JC, Marco O, Causeret S, Gimbergues P, Fiorenza F, Chaigneau L, Guillemin F, Guilloit JM, Dujardin F, Spano JP, Ruzic JC, Michot A, Soibinet P, Bompas E, Chevreau C, Duffaud F, Rios M, Perrin C, Firmin N, Bertucci F, Le Pechoux C, Le Loarer F, Collard O, Karanian-Philippe M, Brahmi M, Dufresne A, Dupré A, Ducimetière F, Giraud A, Pérol D, Toulmonde M, Ray-Coquard I, Italiano A, Le Cesne A, Penel N, Bonvalot S Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol. 2019 Jun 5. pii: mdz170. doi: 10.1093/annonc/mdz170. [Epub ahead of print] PubMed PMID: 31168580
  13. Carvalho SD, Pissaloux D, Crombé A, Coindre JM, Le Loarer F. Pleomorphic Sarcomas: The State of the Art. Surg Pathol Clin. 2019 Mar;12(1):63-105. doi:10.1016/j.path.2018.10.004. Epub 2018 Dec 17. Review. PubMed PMID: 30709449.
  14. Italiano A, Bringer S, Blay JY, Bonvalot S, Le Cesne A, Le Loarer F, Maingon P. Patterns of Care and Outcome Radiation-Induced Soft Tissue Sarcomas. Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):449-452. doi: 10.1016/j.ijrobp.2018.09.028. Epub 2018 Oct 5. PubMed PMID: 30296473 .
  15. Fourneaux B, Bourdon A, Dadone B, Lucchesi C, Daigle SR, Richard E, Laroche-Clary A, Le Loarer F, Italiano A. Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition. J Hematol Oncol. 2019 Jan 25;12(1):11. doi: 10.1186/s13045-018-0694-1. PubMed PMID: 30683135; PubMed Central  PMCID: PMC6347793.
  16. Assi T, Cavalcanti A, Le Cesne A, Faron M, Honart JF, Hadiji A, Camuzard O, Ibrahim T, LePéchoux C, Mir O, Dumont S, Terrier P, Adam J, Honoré C. Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience.  Clin Transl Oncol. 2019 Jan 17. doi: 10.1007/s12094-019-02034-w. [Epub ahead of print] PubMed PMID: 30656606.
  17. Malouf GG, Beinse G, Adam J, Mir O, Chamseddine AN, Terrier P, Honore C, Spano JP, Italiano A, Kurtz JE, Coindre JM, Blay JY, Le Cesne A. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective  Analysis of the French Sarcoma Group. Oncologist. 2019 Jan 9. pii: theoncologist.2018-0074. doi: 10.1634/theoncologist.2018-0074. [Epub ahead of print] PubMed PMID: 30626710.
  18. Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3. Epub 2018 Nov 23. PubMed PMID: 30477937.
  19. Bouché O, Cesne AL, Rios M, Chaigneau L, Italiano A, Duffaud F, Lecomte T, Arsène D, Manfredi S, Aparicio T, Remy S, Isambert N, Collard O, Priou F, Bertucci F, Sambuc R, Bisot-Locard S, Bourges O, Chabaud S, Blay JY. EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib. PLoS One. 2018 Sep 18;13(9):e0204117. doi: 10.1371/journal.pone.0204117. eCollection 2018. PubMed PMID: 30226855; PubMed Central PMCID: PMC6143255.
  20. Boughzala-Bennadji R, Stoeckle E, Le Péchoux C, Méeus P, Honoré C, Attal J, Duffaud F, De Pinieux G, Bompas E, Thariat J, Leroux A, Bertucci F, Isambert N, Delcambre C, Blay JY, Sunyach MP, Coindre JM, Sargos P, Penel N, Bonvalot S. Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):399-406. doi: 10.1016/j.ijrobp.2018.05.055. Epub 2018 Jun 2. PubMed PMID: 30191871.
  21. Dadone-Montaudié B, Alberti L, Duc A, Delespaul L, Lesluyes T, Pérot G, Lançon A, Paindavoine S, Di Mauro I, Blay JY, de la Fouchardière A, Chibon F, Karanian M, MacGrogan G, Kubiniek V, Keslair F, Cardot-Leccia N, Michot A, Perrin V, Zekri Y, Coindre JM, Tirode F, Pedeutour F, Ranchère-Vince D, Le Loarer F, Pissaloux D. Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions. Mod Pathol. 2018 Nov;31(11):1683-1693. doi: 10.1038/s41379-018-0089-4. Epub 2018 Jun 28. PubMed PMID: 29955147.
  22. Fayet Y, Coindre JM, Dalban C, Gouin F, De Pinieux G, Farsi F, Ducimetière F, Chemin-Airiau C, Jean-Denis M, Chabaud S, Blay JY, Ray-Coquard I. Geographical Accessibility of the Referral Networks in France. Intermediate Results from the IGéAS Research Program. Int J Environ Res Public Health. 2018 Oct 10;15(10). pii: E2204. doi: 10.3390/ijerph15102204. PubMed PMID: 30308955; PubMed Central PMCID: PMC6210416.
  23. Lebellec L, Bertucci F, Tresch-Bruneel E, Ray-Coquard I, Le Cesne A, Bompas E, Blay JY, Italiano A, Mir O, Ryckewaert T, Toiron Y, Camoin L, Goncalves A, Penel N, Le Deley MC. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. BMC Cancer. 2018 Oct 11;18(1):963. doi: 10.1186/s12885-018-4828-1. PubMed PMID: 30305054; PubMed Central PMCID: PMC6180490.
  24. Italiano A, Bringer S, Blay JY, Bonvalot S, Le Cesne A, Le Loarer F, Maingon P. Patterns of care and outcome Radiation-Induced Soft Tissue Sarcomas. Int J Radiat Oncol Biol Phys. 2018 Oct 5. pii: S0360-3016(18)33808-2. doi: 10.1016/j.ijrobp.2018.09.028. PubMed PMID: 30296473.
  25. Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, Gronchi A, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pélissier S, Bellera C. Surrogate endpoints in advanced sarcoma trials: a meta-analysis. Oncotarget. 2018 Oct 2;9(77):34617-34627. doi: 10.18632/oncotarget.26166. eCollection 2018 Oct 2. PubMed PMID: 30349653.